Keros Therapeutics to Present at the Jefferies Virtual London Healthcare Conference

Rhea-AI Summary

Keros Therapeutics, a clinical-stage biopharmaceutical company, will have its President and CEO, Jasbir S. Seehra, present at the Jefferies Virtual London Healthcare Conference on November 18 at 9:05 am ET. The event will be webcast live and archived on the company's website for 90 days. Keros focuses on developing treatments for hematological and musculoskeletal disorders with high unmet medical needs, including its lead product candidates KER-050, KER-047, and KER-012, targeting conditions like anemia and osteoporosis.

LEXINGTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D. will present at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18^th at 9:05 am ET.

The presentation will be webcast live and archived in the Investors section of the Keros website at https://ir.kerostx.com/. A replay will be available for 90 days following the conclusion of the event.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-Beta, or TGF-ß, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros’ third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

Investor Contact:
Julia Balanova
jbalanova@soleburytrout.com
646-378-2936

FAQ

When is Keros Therapeutics presenting at the Jefferies Virtual London Healthcare Conference?

Keros Therapeutics will present on November 18 at 9:05 am ET.

Who is presenting at the Jefferies Virtual London Healthcare Conference for Keros?

Jasbir S. Seehra, Ph.D., the President and CEO of Keros, will present.

Where can I watch the Keros Therapeutics presentation?

The presentation will be available for live streaming and archived on the Keros website.

What are the main product candidates of Keros Therapeutics?

Keros' main product candidates include KER-050, KER-047, and KER-012.

What disorders does Keros Therapeutics aim to treat?

Keros aims to treat hematological and musculoskeletal disorders, including anemia and osteoporosis.